Practice patterns in haemophilia A therapy - A survey of treatment centres in the United States

Haemophilia

Volumn 9, Issue 5, 2003, Pages 549-554

  Butler, Regina B ^a   McClure, Wilma ^b   Wulff, Karen ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catheters; Demography; Factor VIII; Haemophilia A; Haemorrhage; Indwelling; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTHROPATHY; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH CARE NEED; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUESTIONNAIRE; SECONDARY PREVENTION; TEACHING HOSPITAL; UNITED STATES; VASCULAR ACCESS;

EID: 0141955858     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00792.x     Document Type: Article

References (29)

1. Center for Disease Control and Prevention. Report on the universal data collection program, 2002. http://www.cdc.gov/ncidod/dastlr/Hematology/udc0102.pdf
2. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendations 117, MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding), 2001. http://www.hemophilia.org/programs/masac/masac/masac117.htm
3. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
4. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The orthopaedic outcome study group. J Intern Med 1994; 236: 391-9.
6. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S. A prophylactic program in the United States: experience and issues. Sem Hematol 1994; 31: 10-2.
7. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
8. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
9. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
10. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
11. Ljung RC. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost 1999; 82: 525-30.
12. Ljung R, Aronis-Vournas S, Kurnik-Auberger K, van den Berg M, Chambost H, Claeyssens S et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
13. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
14. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Product choice and haemophilia treatment in the Netherlands. Haemophilia 2001; 7: 96-8.
15. Fischer K, van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
16. Aznar JA, Magallon M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6.
17. van den Berg HM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Hemophilia prophylaxis in the Netherlands. Sem Hematol 1994; 31: 13-5.
18. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
19. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
20. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 3): S166-70.
21. Vidler V. Use of port-a-caths in the management of paediatric haemophilia. Prof Nurse 1994; 10: 48-50.
22. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
23. Collins PW, Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99: 206-8.
24. Ljung R, Petrini P, Lindgren AK, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918-20.
25. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1224-8.
26. Miller K, Buchanan GR, Zappa S et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998; 132: 934-8.
27. Geraghty S, Kleinert D. Use and morbidity of venous access devices in patients with hemophilia. J Intraven Nurs 1998; 21: 70-5.
28. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66-70.
29. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.